Precision medicine and data
Prenosis Sepsis ImmunoScore
FDA De Novo-authorized AI/ML software that assigns adult emergency department or hospital patients to sepsis risk categories within a clinician-reviewed workflow.
Last updated: June 5, 2026
Back to directoryCaris Life Sciences medical AI product profile
Precision medicine company applying molecular science and AI to oncology testing, data, and treatment-insight workflows.
Precision medicine and data
Best fit
Oncology teams evaluating molecular profiling and AI-assisted insight workflows for cancer care and research.
- Primary use case
- AI-enabled molecular profiling, precision oncology insights, and tumor board reporting
- Audience
- Oncology practices, cancer centers, molecular tumor boards, life-sciences teams, and precision-oncology programs
- Risk level
- High
- Pricing signal
- Clinical testing, enterprise, and life-sciences pricing varies; verify current terms.
- Official sources
- 3 official sources
Compare within workflow: Precision medicine and data · comparison shortlist · source index
Regulatory, privacy, evidence, and workflow lens
Product-specific review. These product-specific signals summarize what the cited sources imply before treating Caris Life Sciences as safe for a local clinical, operational, or research workflow.
| Regulatory / FDA | Review the selected assay, laboratory status, report language, AI signature, and molecular tumor board use separately instead of treating Caris as one uniform AI product. |
|---|---|
| Privacy | Confirm patient consent, molecular-data handling, data-use permissions, portal access, retention, and whether research, biopharma, or clinical workflows have different terms. |
| Evidence | Check the biomarker, signature, and treatment-association evidence for the cancer type and report context before using outputs in clinical recommendations. |
| Workflow | Route AI insights through oncologist, molecular pathology, genetic counseling, payer, and tumor board review as appropriate for the test and patient context. |
Where Caris Life Sciences fits
Caris describes itself as a molecular science and AI company focused on precision medicine, and has announced Caris AI Insights signatures used in molecular tumor board reporting.
Not for: Using AI signatures, molecular reports, or treatment suggestions without oncologist review and test-specific clinical context.
What to verify before using Caris Life Sciences
- Which test, report, or AI insight is being used and its exact clinical role.
- Regulatory, laboratory, and reimbursement status for the selected assay.
- Evidence supporting the biomarker, signature, or treatment association.
- Patient consent, data-use terms, and molecular tumor board review process.
Source links
Use these links to confirm current claims, terms, regulatory status, pricing, and deployment requirements.
- www.carislifesciences.com
- www.carislifesciences.com / about
- investor.carislifesciences.com / news-releases / news-release-details
Related medical AI products
Precision medicine and data
Anumana ECG-AI
Cardiovascular AI platform using standard 12-lead ECGs to surface signals such as low ejection fraction, pulmonary hypertension, and cardiac amyloidosis for clinician follow-up.
Precision medicine and data
Eko Health SENSORA
FDA-cleared cardiovascular detection platform that pairs Eko digital stethoscopes with AI-supported ECG and heart-sound analysis for supervised point-of-care screening.
Precision medicine and data
AliveCor Kardia 12L
Portable AI-powered 12-lead ECG system that uses a reduced leadset and KAI 12L algorithms to support clinician-reviewed cardiac determinations.